Story

Hims & Hers Stock Dips as Major Earnings Miss Overshadows Revenue Beat

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Hims & Hers Stock Dips as Major Earnings Miss Overshadows Revenue Beat
Text size
Background

Shares of Hims & Hers Health (NYSE: HIMS) slipped 1.5% in after-hours trading after the telehealth company reported second-quarter results that featured a significant earnings miss, overshadowing strong revenue growth and an increased full-year forecast.

Quarterly Results Breakdown

The company announced Q2 2026 revenue of $753 million, a 38% increase year-over-year that surpassed analyst expectations. However, this top-line strength was offset by a much wider-than-expected loss.

Hims & Hers posted a loss per share of -$0.37, missing the consensus estimate of a -$0.05 loss by a substantial margin. According to the company, the shortfall was driven by a 12-percentage-point contraction in gross margin, which it attributed to its ongoing transition from compounded to more expensive branded GLP-1 weight-loss medications.

Upgraded Outlook Fails to Lift Shares

Despite the profitability challenges, management provided an optimistic outlook for the remainder of the year. Hims & Hers raised its full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion, up from a prior forecast of $2.8 billion to $3.0 billion and above the analyst consensus of $3.05 billion.

Sample IUX Markets – In-articleAd

For the upcoming third quarter, the company projects revenue between $880 million and $900 million, with adjusted EBITDA expected to be in the range of $75 million to $95 million.

Investor Concerns Weigh on Sentiment

Investors appeared to focus on the near-term profitability pressures and other headwinds. Before the report, Truist Securities had reiterated a Hold rating on the stock with a $27 price target. Furthermore, card data cited by Investing.com indicated that GLP-1 billings declined 1% month-over-month in July after expanding 32% in June, raising questions about near-term growth momentum.

A legal overhang also continues to weigh on the stock. Hims & Hers faces a lawsuit from the Federal Trade Commission filed in late July over allegations of sharing sensitive user health data, in addition to investigations from multiple law firms regarding alleged securities violations. The combination of the earnings miss, margin pressure, and unresolved legal risks appeared to outweigh the positive guidance in the market's initial reaction.

Read next

More on Stocks
Back to latest news

LATEST